Shots :
- Regeneron highlighted the data at RAD’25 from the P-IV (DISCOVER) study evaluating Dupixent in pts (N=120) with atopic dermatitis with skin of color that received Dupixent as monotx. Q2W based on weight after loading dose: 200mg for 30-60kg pts & 300mg for ≥60kg pts
- Dupixent achieved a ≥75% improvement in overall disease severity (EASI-75) in 76% of adults and adolescents with moderate-to-severe atopic dermatitis with skin of color at 24wks.
- Pts experienced clinically meaningful improvements in itch (53% achieved ≥4-point reduction in pruritus), a 53% reduction in post-inflammatory hyperpigmentation, and a dramatic decrease in dry skin (from 78% to 18% reporting severe dryness)
Ref: Regeneron | Image: Regeneron| Press Release
Related News:- LEX Diagnostics Seeks 510(k) Clearance and CLIA Waiver Status for its VELO system to Deliver Highly Sensitive PCR Results
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
